Acute myeloid leukemia (AML), the second most common leukemia in children, is hard to treat and has a five-year survival rate of just 65 to 70%, according to the American Cancer Society. While immunotherapies like monoclonal antibodies or CAR T-cell therapy are effective for certain blood ca...
参考文献：Slezak, A. J., et al. (2024). Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia. Blood Advances. doi.org/10.1182/bloodadvances.2023012529.
With the development of science and technology, the treatment of leukemia has been made great progress, but the cure of the disease is still unsolved, and the 5-year survival rate is only 25%3,4,5,6,7. Although AML patients after treatment, the condition has been greatly improved, but ...
Molecular testing forAML Acute Myeloid Leukemia (AML) is one of a group of highly aggressive, potentially fatal leukemias, and perhaps one of the most aggressive leukemia, with a 5-year survival rate of approximately 25%1. Therapy can be effective and ...
because of GVL. In this regard, donors’ immune cells recognize and attack to remaining leukemia as soon as injected, which does not happen in autologous HSCT [50,51]. Clinical investigations revealed a significant survival rate among AML patients after receiving alloHSCT. However, there are ...
Improved Survival Rates Among Acute Myeloid Leukemia (AML) Patients 65 to 74 Years: Population-Based Estimates Over Three Decades,Mya S TheinAhmedin JemalMaria R. BaerWilliam B ErshlerJerome W Yates
We were interested in determining the effect of lower TRM with AutoPB shown in many series to be 5–10%. We compared TRM, relapse, leukemia-free survival (LFS), and overall survival (OS) of 1133 patients 19–60 years of age in CR1 who underwent HLA-identical myeloablative BM or ...
MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004; 18: 1380–1390. Article CAS Google Scholar van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ . Detection of minimal ...
The Treatment of Acute Myeloid Leukemia in First Relapse: A Comprehensive Review of the Literature Twenty years of published literature was reviewed for chemotherapy regimens used to treat patients with acute myeloid leukemia (AML) in first relapse. Thir... Leopold,Lance,H.,... - 《Leukemia & ...
Median overall survival (OS) was longer in patients achieving RBC-TI X8 weeks (4.3 vs 2.0 years in non-responders; Po0.0001) or cytogenetic response (4.9 vs 3.1 years in non-responders; P ¼ 0.010). Time to acute myeloid leukemia (AML) progression was longer in patients achieving RBC-...